An Open Label, Clinical Study to Evaluate the Efficacy and Safety of Turmeric Oral Rinse in Oral Mucositis During Cancer Chemotherapy and Radiotherapy

The Himalaya Drug Company0 个研究点目标入组 40 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•1 Subjects with confirmed histopathologically with head and neck cancer (according to TNM classification) preferably oropharyngeal scheduled to receive chemotherapy or radiotherapy as a standard care.
•2 Subjects with history or prone to develop oral mucositis during cancer chemotherapy or radiotherapy.
•3 Subjects aged >18 years of either the sex.
•4 Subjects willing to give a written informed consent and follow the schedule of the study as per the protocol.

•1 Has participated in a similar clinical investigation in the past four weeks.
•2 Severe uncontrolled systemic disorders, diabetes, Hypertension, or genetic and endocrinal disorders.
•3 Has used a similar product in the past four weeks.
•4 Subjects who refused to sign informed consent.
•5 Pregnant and lactating women.

发起方